BioBeats, which creates evidence-based wellbeing products for preventative health, has been acquired by global health company, Huma, formerly Medopad.
BioBeats is part of the Oxford Sciences Innovation (OSI) portfolio, which in 2018 co-led with White Cloud and IQ Capital a £2.4 million funding round for the company, enabling it to expand its research and product capabilities.
“We share a vision with Huma for pioneering preventative health.
“We want people to go from simply surviving to thriving. By creating clinically-validated products to predict, diagnose and treat mental health disorders, we allow everyone to flourish. With Huma’s experience, global partners and innovation capabilities, we look forward to joining the team to help people live longer, fuller lives.”
The company’s flagship product BioBase is a mobile app, paired with biosensors and a wearable device, which gathers biometric data such as heart rate variability, and psychometric measures like mood journaling, to give users a personalised wellbeing score, fostering an increased understanding of their mental wellbeing. Combining applied research and AI, BioBase improves mental health through tailored insights, biofeedback tools and digital therapeutics for a preventative mental health intervention.
Huma’s acquisition of BioBeats is part of a major move into the UK AI and wearable technology sector which has included Huma rebranding (it was formerly Medopad), and acquiring TLT, a Hertfordshire-based medical technology firm with a wrist-worn sensor device that provides continuous blood pressure monitoring.
The rebrand and acquisitions support the company’s mission to use insights gathered by remote monitoring to help healthcare, life sciences and innovation partners understand, treat and prevent poor health.
Dan Vahdat, founder and CEO of Huma, said: “Every day our bodies generate millions of unrecorded data points, masses of information previously unseen. We believe that this data can open up new insights on people’s health, just as mapping and visualising the genome has done. This previously unseen data represents a category called digital biomarkers, the unique signatures created as we walk, talk and move. Digital biomarkers may help tell us what causes disease, how they progress, and potentially how we can prevent disease. BioBeats and TLT enable our partners to have a more holistic sense of people’s health and wellbeing through better data.”